Table 2.

Estimated 5-year discounted health outcomes and cost-effectiveness results of the current treatment mix (week 24 response assessment) and certolizumab pegol risk-sharing scheme (week 12 response assessment)

	Current treatment mix			CZP RSS			Difference
	Mean	95% CI		Mean	95% CI		Mean	95% CI
Life yearsa	4.522	4.487	4.548	4.526	4.494	4.550	0.004	−0.004	0.017
Proportion of time with response
No ACR20	48%	42%	54%	43%	38%	49%	−5%-units	−13%-units	3%-units
ACR20 (or better)	52%	46%	58%	57%	51%	62%	5%-units	−3%-units	13%-units
ACR50 (or better)	34%	27%	41%	40%	32%	47%	6%-units	−5%-units	17%-units
ACR70 (or better)	17%	9%	24%	18%	6%	30%	1%-units	−12%-units	14%-units
QALYsa	2.304	2.086	2.505	2.332	2.120	2.545	0.028	−0.047	0.093
Work days losta	393.0	360.3	441.8	369.5	340.9	396.9	−23.5	−80.9	19.9
Cost per patient (€)a	139,967	133,929	151,717	132,101	127,024	137,244	−7866	−20,410	−60
Abatacept (first line)	1306	974	1601	0	0	0	−1306	−1601	−974
Adalimumab (first line)	12,694	10,764	14,303	0	0	0	−12,694	−14,303	−10,764
CZP (first line)	1127	1010	1216	25,632	20,889	29,582	24,505	19,747	28,450
Etanercept (first line)	8970	7006	10,612	0	0	0	−8970	−10,612	−7006
Golimumab (first line)	3490	2616	4333	0	0	0	−3490	−4333	−2616
Other first-line costsb	3271	2976	3541	2796	2267	3237	−475	−1075	48
Subsequent treatment	27,650	25,552	30,418	28,319	25,036	32,379	669	−3581	5280
Hospitalizations, travel	9288	8836	10,087	8975	8613	9352	−313	−1154	206
Productivity losses	72,171	66,166	81,121	67,850	62,597	72,875	−4321	−14,861	3647
RSS refund	0	0	0	−1472	−2163	−899	−1472	−2163	−899

CI confidence interval, CZP certolizumab pegol, QALYs quality-adjusted life years, RSS risk-sharing scheme

^aDiscounted

^bIncludes administration, monitoring, and adverse event costs